NCT07038200 - A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

June 10, 2025

Primary Completion Date

May 31, 2028

Study Completion Date

July 31, 2028

Conditions

Facioscapulohumeral Muscular DystrophyFSHDFSHD - Facioscapulohumeral Muscular DystrophyFSHD1FSHD2Fascioscapulohumeral Muscular DystrophyFascioscapulohumeral Muscular Dystrophy Type 1Fascioscapulohumeral Muscular Dystrophy Type 2Facioscapulohumeral Muscular Dystrophy 1Facioscapulohumeral DystrophyFacio-Scapulo-Humeral DystrophyFacioscapulohumeral Muscular Dystrophy 2Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1)FSH Muscular DystrophyLandouzy Dejerine DystrophyLandouzy-Dejerine Muscular DystrophyLandouzy-Dejerine Syndrome

Interventions

DRUG

AOC-1020

Placebo

DRUG

Placebo

Placebo will be administered by intravenous (IV) infusion.

Trial Locations (14)

14642

RECRUITING

University of Rochester Medical Center, Rochester

19104

RECRUITING

University of Pennsylvania, Philadelphia

21205

RECRUITING

Kennedy Krieger Institute, Baltimore

23298

RECRUITING

Virginia Commonwealth University, Richmond

27708

RECRUITING

Duke University, Durham

32608

RECRUITING

University of Florida, Gainesville

43221

RECRUITING

Ohio State University, Columbus

52242

RECRUITING

University of Iowa, Iowa City

66205

RECRUITING

Kansas University Medical Center, Kansas City

78229

RECRUITING

University of Texas Health Science Center at San Antonio, San Antonio

80045

RECRUITING

University of Colorado, Denver

92868

RECRUITING

University of California Irvine, Orange

94304

RECRUITING

Stanford University, Palo Alto

01655

RECRUITING

University of Massachusetts, Worcester